Fluorouracil, Oxaliplatin, and Leucovorin in Treating Patients With Metastatic Stomach Cancer or Gastroesophageal Junction Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

January 31, 2011

Study Completion Date

February 28, 2011

Conditions
Gastric Cancer
Interventions
DRUG

fluorouracil

Given through a vein over 5 minutes and then continuously over 46 hours on days 1 and 15.

DRUG

leucovorin calcium

through a vein over 2 hours on days 1 and 15.

DRUG

oxaliplatin

500 ml D5W through a vein over 2 hours on days 1 and 15.

GENETIC

gene expression analysis

Blood collection

GENETIC

polymorphism analysis

Blood collection

GENETIC

protein expression analysis

Blood collection

OTHER

pharmacological study

Blood collection

Trial Locations (5)

37064

Vanderbilt-Ingram Cancer Center - Cool Springs, Nashville

Vanderbilt-Ingram Cancer Center at Franklin, Nashville

63110

Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis, St Louis

27599-7295

Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill

37232-6838

Vanderbilt-Ingram Cancer Center, Nashville

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Vanderbilt-Ingram Cancer Center

OTHER

NCT00514020 - Fluorouracil, Oxaliplatin, and Leucovorin in Treating Patients With Metastatic Stomach Cancer or Gastroesophageal Junction Cancer | Biotech Hunter | Biotech Hunter